Kedrion S.p.A.
UkraineAll drugs from this manufacturer
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia B (congenital factor IX deficiency) and may also be used to treat acquired deficiency of this factor.
Dosage form: powder and solvent for infusion solution
Active substance Dosage human blood coagulation factor ix 500 IU ATC: B02BD04
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia B (congenital factor IX deficiency), and may also be used in acquired deficiency of this factor.
Dosage form: powder and solvent for infusion solution
Active substance Dosage human blood coagulation factor ix 1000 IU ATC: B02BD04
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (inherited factor VIII deficiency), as well as for the treatment of acquired deficiency of this factor or hemophilia patients with the presence of antibodies (inhibitors).
Dosage form: powder and solvent for infusion solution
Active substance Dosage human blood coagulation factor viii 500 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (inherited factor VIII deficiency), as well as for the treatment of acquired deficiency of this factor or hemophilia patients with the presence of antibodies (inhibitors).
Dosage form: powder and solvent for infusion solution
Active substance Dosage human blood coagulation factor viii 1000 IU ATC: B02BD02
-
The drug is used to restore and maintain circulating blood volume in patients experiencing a deficit where the use of colloids is indicated.
Dosage form: solution for infusion
Active substance Dosage plasma proteins containing not less than 95 % albumin 200 g/l ATC: B05AA01
-
The drug is used for the prevention of Rh isoimmunization in women of childbearing age with a negative Rh factor. This applies to both routine prophylaxis during pregnancy and measures following pregnancy complications or the birth of an Rh(D)-positive child. It is also used for the treatment of women following incompatible blood transfusion.
Dosage form: solution for injection
Active substance Dosage human immunoglobulin g with antibodies to erythrocyte d antigen 150 mcg 2 ml ATC: J06BB01
-
The drug is used for the emergency prevention of tetanus in the presence of infected wounds (if the person has not been properly vaccinated or their status is unknown), as well as for the treatment of clinically manifest tetanus.
Dosage form: solution for injection
Active substance Dosage human immunoglobulin against tetanus toxin 250 IU/ml ATC: J06BB02
-
The drug is used for the emergency prevention of tetanus in the presence of infected wounds (if the person has not been properly vaccinated or their immunization status is unknown), as well as for the treatment of clinically manifest tetanus.
Dosage form: solution for injection
Active substance Dosage human immunoglobulin g with antibodies to tetanus toxin 500 IU/2 ml ATC: J06BB02
-
The drug is used for the treatment of bleeding and the prevention of bleeding before surgery. It is applied in cases of acquired clotting factor deficiency (e.g., due to the intake of vitamin K antagonists) or in cases of congenital factor deficiency if no specialized drug is available.
Dosage form: powder for solution for infusion
Active substance Dosage human blood coagulation factor ix 500 IU human blood coagulation factor ii 500 IU human blood coagulation factor x 400 IU ATC: B02BD01
-
The drug is used for the treatment of bleeding and its prevention before surgery. This applies to cases where there is a deficiency of blood clotting factors in the body, for example, due to the intake of certain medications (vitamin K antagonists) or due to congenital deficiency of these factors.
Dosage form: powder and solvent for infusion solution
Active substance Dosage human blood coagulation factor ix 500 IU human blood coagulation factor ii 500 IU human blood coagulation factor x 400 IU ATC: B02BD01